“The existing predicament has uncovered some structural weaknesses while in the EU’s medicines source chain and a substantial dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides explained. She encouraged that provide chain problems be dealt with within an EU pharmaceutical system anticipated to be i